43 results on '"El-abed, S."'
Search Results
2. Gene expression profile at week 2 of neoadjuvant therapy course predicts outcome in HER2-positive breast cancer patients: an explorative analysis from NeoALTTO
- Author
-
Di Cosimo, S., primary, Pizzamiglio, S., additional, Sotiriou, C., additional, Ciniselli, C.M., additional, Triulzi, T., additional, de Cecco, L., additional, El-Abed, S., additional, Izquierdo, M., additional, de Azambuja, E., additional, Saura, C., additional, Huober, J., additional, Untch, M., additional, Lang, I., additional, Loi, S., additional, Tagliabue, E., additional, Rubio, I.T., additional, Vingiani, A., additional, Colombo, M.P., additional, Verderio, P., additional, and Pruneri, G., additional
- Published
- 2022
- Full Text
- View/download PDF
3. 139MO Identification of biologically-driven HER2-positive breast cancer subgroups associated with prognosis after adjuvant trastuzumab in the ALTTO trial
- Author
-
Rediti, M., primary, Venet, D., additional, Joaquin Garcia, A., additional, Agbor-tarh, D., additional, Maetens, M., additional, Vincent, D., additional, Majjaj, S., additional, El-Abed, S., additional, Liu, M.C., additional, Di Cosimo, S., additional, Piccart, M., additional, Pusztai, L., additional, Loi, S., additional, Salgado, R.F., additional, Viale, G., additional, Rothé, F., additional, and Sotiriou, C., additional
- Published
- 2022
- Full Text
- View/download PDF
4. 1814O Breastfeeding in women with hormone receptor-positive breast cancer who conceived after temporary interruption of endocrine therapy: Results from the POSITIVE trial
- Author
-
Azim, H.A., Jr, Niman, S., Partridge, A.H., Ruggeri, M., Colleoni, M.A., Saura Manich, C., Shimizu, C., Satersdal, A., Kroep, J.R., Gelmon, K.A., Amant, F., Mailliez, A., Moore, H., Ferreiro, T., El-abed, S., Gelber, R.D., Pagani, O., and Peccatori, F.A.
- Published
- 2024
- Full Text
- View/download PDF
5. Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab
- Author
-
Ligorio, F, Di Cosimo, S, Verderio, P, Ciniselli, CM, Pizzamiglio, S, Castagnoli, L, Dugo, M, Galbardi, B, Salgado, R, Loi, S, Michiels, S, Triulzi, T, Tagliabue, E, El-Abed, S, Izquierdo, M, de Azambuja, E, Nuciforo, P, Huober, J, Moscetti, L, Janni, W, Coccia-Portugal, MA, Corsetto, PA, Belfiore, A, Lorenzini, D, Daidone, MG, Vingiani, A, Gianni, L, Pupa, SM, Bianchini, G, Pruneri, G, Vernieri, C, Ligorio, F, Di Cosimo, S, Verderio, P, Ciniselli, CM, Pizzamiglio, S, Castagnoli, L, Dugo, M, Galbardi, B, Salgado, R, Loi, S, Michiels, S, Triulzi, T, Tagliabue, E, El-Abed, S, Izquierdo, M, de Azambuja, E, Nuciforo, P, Huober, J, Moscetti, L, Janni, W, Coccia-Portugal, MA, Corsetto, PA, Belfiore, A, Lorenzini, D, Daidone, MG, Vingiani, A, Gianni, L, Pupa, SM, Bianchini, G, Pruneri, G, and Vernieri, C
- Abstract
BACKGROUND: Despite huge efforts to identify biomarkers associated with long-term clinical outcomes in patients with early-stage HER2-positive breast cancer (HER2+ BC) treated with (neo)adjuvant anti-HER2 therapy, no reliable predictors have been identified so far. Fatty acid uptake, a process mediated by the transmembrane transporter CD36, has recently emerged as a potential determinant of resistance to anti-HER2 treatments in preclinical HER2+ BC models. METHODS: Here, we investigated the association between baseline intratumor CD36 gene expression and event-free survival in 180 patients enrolled in the phase III trial Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization (NeoALTTO), which randomly assigned stage II-III HER2+ BC patients to receive neoadjuvant lapatinib, trastuzumab, or lapatinib-trastuzumab in combination with chemotherapy. To this aim, we selected NeoALTTO trial patients for whom pretreatment whole transcriptomic data were available. The main study results were validated in an independent cohort of patients enrolled in the neoadjuvant phase II trial NeoSphere. RESULTS: In 180 NeoALTTO patients, high intratumor CD36 expression was independently associated with worse event-free survival in patients treated with trastuzumab-based therapy (hazard ratio [HR] = 1.72, 95% confidence interval [CI] = 1.20 to 2.46), but not with lapatinib-based (HR = 1.02, 95% CI = 0.68 to 1.53) or trastuzumab-lapatinib-based (HR = 1.08, 95% CI = 0.60 to 1.94) therapy. Among 331 NeoSphere patients evaluated, high CD36 expression was independently associated with worse patient disease-free survival in both the whole study cohort (HR = 1.197, 95% CI = 1.002 to 1.428) and patients receiving trastuzumab-based neoadjuvant therapy (HR = 1.282, 95% CI = 1.049 to 1.568). CONCLUSIONS: High CD36 expression predicts worse clinical outcomes in early-stage HER2+ BC treated with trastuzumab-based neoadjuvant therapy.
- Published
- 2022
6. Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial
- Author
-
Venet, D, Rediti, M, Maetens, M, Fumagalli, D, Brown, DN, Majjaj, S, Salgado, R, Pusztai, L, Harbeck, N, El-Abed, S, Wang, Y, Saura, C, Gomez, H, Semiglazov, VF, de Azambuja, E, Huober, J, Nuciforo, P, Di Cosimo, S, Piccart, M, Loi, S, Rothe, F, Sotiriou, C, Venet, D, Rediti, M, Maetens, M, Fumagalli, D, Brown, DN, Majjaj, S, Salgado, R, Pusztai, L, Harbeck, N, El-Abed, S, Wang, Y, Saura, C, Gomez, H, Semiglazov, VF, de Azambuja, E, Huober, J, Nuciforo, P, Di Cosimo, S, Piccart, M, Loi, S, Rothe, F, and Sotiriou, C
- Abstract
PURPOSE: The heterogeneity of response to anti-HER2 agents represents a major challenge in patients with HER2-positive breast cancer. To better understand the sensitivity and resistance to trastuzumab and lapatinib, we investigated the role of copy number aberrations (CNA) in predicting pathologic complete response (pCR) and survival outcomes in the NeoALTTO trial. EXPERIMENTAL DESIGN: The neoadjuvant phase III NeoALTTO trial enrolled 455 patients with HER2-positive early-stage breast cancer. DNA samples from 269 patients were assessed for genome-wide copy number profiling. Recurrent CNAs were found with GISTIC2.0. RESULTS: CNA estimates were obtained for 184 patients included in NeoALTTO. Among those, matched transcriptome and whole-exome data were available for 154 and 181 patients, respectively. A significant association between gene copy number and pCR was demonstrated for ERBB2 amplification. Nevertheless, ERBB2 amplification ceased to be predictive once ERBB2 expression level was considered. GISTIC2.0 analysis revealed 159 recurrent CNA regions. Lower copy number levels of the 6q23-24 locus predicted absence of pCR in the whole cohort and in the estrogen receptor-positive subgroup. 6q23-24 deletion was significantly more frequent in TP53 wild-type (WT) compared with TP53-mutated, resulting in copy number levels significantly associated with lack of pCR only in the TP53 WT subgroup. Interestingly, a gene-ontology analysis highlighted several immune processes correlated to 6q23-24 copy number. CONCLUSIONS: Our analysis identified ERBB2 copy number as well as 6q23-24 CNAs as predictors of response to anti-HER2-based treatment. ERBB2 expression outperformed ERBB2 amplification. The complexity of the 6q23-24 region warrants further investigation.
- Published
- 2021
7. 237 (PB-061) Poster - Gene expression profile at week 2 of neoadjuvant therapy course predicts outcome in HER2-positive breast cancer patients: an explorative analysis from NeoALTTO
- Author
-
Di Cosimo, S., Pizzamiglio, S., Sotiriou, C., Ciniselli, C.M., Triulzi, T., de Cecco, L., El-Abed, S., Izquierdo, M., de Azambuja, E., Saura, C., Huober, J., Untch, M., Lang, I., Loi, S., Tagliabue, E., Rubio, I.T., Vingiani, A., Colombo, M.P., Verderio, P., and Pruneri, G.
- Published
- 2022
- Full Text
- View/download PDF
8. DIVERSITY OF MYCORRHIZAL FUNGI ARBUSCULAR AT PHOSPHATES SLUDGE, KHOURIBGA REGION (MOROCCO).
- Author
-
EL Gabardi, S., Chliyeh, M., Touhami, A. Ouazzani, EL Modafar, C., Filalimaltouf, A., EL Abed, S., Koraichi, S. Ibnsouda, Soumia, A., Moukhli, A., Benkirane, R., and Douira, A.
- Subjects
MYCORRHIZAL fungi ,PHOSPHATES ,PLANT species ,RHIZOSPHERE - Abstract
Arbuscular mycorrhizal fungi to have been sought in the sludge of phosphates and various plant species of the region of Khouribga (Morocco). The density of spores of mycorrhizal fungi in phosphates sludge is low, ranging from 43 and 4 spores / 100 g soil. Some species are specific, case of Glomus aureum encountered at the level of the 1.5 basin; while others are common, case of Glomus intraradices present in all studied sites. The preliminary morphological identification of the isolated species have allowed to highlight the presence of 31 species belonging to 4 genera (Glomus: 16 species, Acaulospora: 9 species, Entrophospora: 3 species, Scutellospora: 3 species), 4 families (Glomaceae, Acaulosporaceae, Scutellosporaceae, and Entrophosporaceae), and 2 Orders (Glomerales, and Diversisporales). This study demonstrated the wealth of sludge in arbuscular mycorrhizal fungi. This wealth could be exploited in the production of a phospho-compost based on a composite endomycorrhizal inoculum, phosphate waste and organic residues. [ABSTRACT FROM AUTHOR]
- Published
- 2019
9. Re-evaluation of the properties of a selected lubricant after adding Zinc oxide as a Nanoadditive
- Author
-
El Abed, S., primary, El –Sherbini, E., additional, and Mohamed, M., additional
- Published
- 2016
- Full Text
- View/download PDF
10. Fungicidal activity of four essential oils fromPiper capense,Piper borbonenseandVetiveria zizanoidesgrowing in Comoros against fungi decay wood
- Author
-
Soidrou, S.H., primary, Farah, A., additional, Satrani, B., additional, Ghanmi, M., additional, Jennan, S., additional, Hassane, S.O.S., additional, Lachkar, M., additional, El Abed, S., additional, Ibnsouda Koraichi, S., additional, and Bousta, D., additional
- Published
- 2013
- Full Text
- View/download PDF
11. Biodegradation of Poly(ester urethane)s by Bacillus subtilis.
- Author
-
Nakkabi, A., Sadiki, M., Fahim, M., Ittobane, N., Ibnsouda Koraichi, S., Barkai, H., and El abed, S.
- Abstract
Polyurethanes (PURs) are polymers that can be generated by a step-growth polyaddition reaction of diisocyanates with polyols. The number of well-developed chemical procedures applicable to their manufacture, and the diversity of chemical structures in which polyurethanes can be built, account for the widespread use of these materials in the last few decades for both domestic and technical applications due to its excellent mechanical and thermal properties and their high resistance to the climatic changes. Nevertheless, its high resistance to degradation in aqueous media or bymicroorganism constitutes not only a great disadvantage for its use as material in medical applications (vascular grafts, artificial heart diaphragms, valves, catheters...) but also as one of the sources of the pollution of the environment. In this work, we report the degradation of a commercial poly (ester-urethane) by microorganisms isolated from cedar wood. This is the first study that demonstrates the degradation of polyurethane by isolated microorganisms from wood. Analyses were carried out by Infrared spectroscopy. [ABSTRACT FROM AUTHOR]
- Published
- 2015
12. Fungicidal activity of four essential oils from Piper capense , Piper borbonense and Vetiveria zizanoides growing in Comoros against fungi decay wood.
- Author
-
Soidrou, S.H., Farah, A., Satrani, B., Ghanmi, M., Jennan, S., Hassane, S.O.S., Lachkar, M., El Abed, S., Ibnsouda Koraichi, S., and Bousta, D.
- Subjects
MEDICINAL plants ,PLANT species ,ESSENTIAL oils ,PIPER (Genus) ,SESQUITERPENES - Abstract
For valorization and diversification of medicinal plants used in Comoros, we are interested in three species growth in this archipelago. Four essential oils were extracted from these plants and used in this study. Essential oils were obtained by hydrodistillation and analyzed by gas chromatography (GC) and GC–mass spectrometry (GC–MS). Sesquiterpene compounds are predominant inPiper borbonenseandVetiveria zizanoidesessential oils but forPiper capenseessential oil, monoterpenes are predominant. Essential oils were investigated for their fungicidal activities against four fungi decay wood:Gloeophyllum trabeum(Persoon ex Fries) Murril (ATCC 11539),Poria placenta(Fries) Cooke sensu J. Eriksson (ATCC 9891),Coniophora puteana(Schumacher ex Fries) Karsten (ATCC 9351) andCoriolus versicolor(Linnaeus) Quélet (ATCC 12679). These essential oils showed an in important activity against all strains tested. However, the highest activity was observed inVetiveriaandP. borbonenseessential oils. [ABSTRACT FROM PUBLISHER]
- Published
- 2013
- Full Text
- View/download PDF
13. Fungicidal activity of four essential oils from Piper capense, Piper borbonenseand Vetiveria zizanoidesgrowing in Comoros against fungi decay wood
- Author
-
Soidrou, S.H., Farah, A., Satrani, B., Ghanmi, M., Jennan, S., Hassane, S.O.S., Lachkar, M., El Abed, S., Ibnsouda Koraichi, S., and Bousta, D.
- Abstract
For valorization and diversification of medicinal plants used in Comoros, we are interested in three species growth in this archipelago. Four essential oils were extracted from these plants and used in this study. Essential oils were obtained by hydrodistillation and analyzed by gas chromatography (GC) and GC–mass spectrometry (GC–MS). Sesquiterpene compounds are predominant in Piper borbonenseand Vetiveria zizanoidesessential oils but for Piper capenseessential oil, monoterpenes are predominant. Essential oils were investigated for their fungicidal activities against four fungi decay wood: Gloeophyllum trabeum(Persoon ex Fries) Murril (ATCC 11539), Poria placenta(Fries) Cooke sensu J. Eriksson (ATCC 9891), Coniophora puteana(Schumacher ex Fries) Karsten (ATCC 9351) and Coriolus versicolor(Linnaeus) Quélet (ATCC 12679). These essential oils showed an in important activity against all strains tested. However, the highest activity was observed in Vetiveriaand P. borbonenseessential oils.
- Published
- 2013
- Full Text
- View/download PDF
14. Combined effect of essential oils against bacteria associated with deterioration of historical wood
- Author
-
Moulay SADIKI, El Abed, S., Balouiri, M., Barkai, H., El Bergadi, F. Z., El Farricha, O., and Ibnsouda Koraichi, S.
15. Penicillium italicum, Penicillium griseoroseum and Pseudomonas trivialis are the novel species that degrade cedar wood in historical Moroccan sites
- Author
-
El Bergadi, F., El Abed, S., Laachari, F., and Ibnsouda Koraichi Saad
16. Biodegradation of poly(ester urethane)s by Bacillus subtilis
- Author
-
Nakkabi, A., Sadiki, M., Fahim, M., Ittobane, N., Ibnsouda Koraichi Saad, Barkai, H., and El Abed, S.
17. 1LBA LBA Oral - Adjuvant chemotherapy with or without atezolizumab for stage II and III triple-negative breast cancer: final analysis of the ALEXANDRA/ IMpassion030 phase 3 trial.
- Author
-
McArthur, H., Bailey, A., Saji, S., El-Abed, S., Nader Marta, G., Metzger, O., Seiller, A., Shparyk, Y., Kim, H.J., Bonichon Lamichhane, N., Alonso, J.L., Ellingson, A., Zimina, A., Yamashita, T., Mohan, S., Shao, Z., Viale, G., Piccart, M., Ignatiadis, M., and Gelber, R.
- Subjects
- *
BREAST tumor treatment , *THERAPEUTIC use of monoclonal antibodies , *BREAST tumors , *CONFERENCES & conventions , *ADJUVANT chemotherapy , *TUMOR classification - Published
- 2024
- Full Text
- View/download PDF
18. End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO
- Author
-
Serena Di Cosimo, Chiara M. Ciniselli, Sara Pizzamiglio, Vera Cappelletti, Marco Silvestri, Sarra El-Abed, Miguel Izquierdo, Mohammed Bajji, Paolo Nuciforo, Jens Huober, David Cameron, Stephen Chia, Henry L. Gomez, Marilena V. Iorio, Andrea Vingiani, Giancarlo Pruneri, Paolo Verderio, Institut Català de la Salut, [Di Cosimo S, Cappelletti V, Silvestri M] Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. [Ciniselli CM, Pizzamiglio S] Unit of Bioinformatics and Biostatistics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. [El-Abed S] Breast International Group, Brussels, Belgium. [Nuciforo P] Molecular Oncology Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Cancer Research ,Mama - Càncer - Prognosi ,MicroARN ,Therapeutics::Combined Modality Therapy::Neoadjuvant Therapy [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT] ,neoplasias::neoplasias por localización::neoplasias de la mama [ENFERMEDADES] ,Oncology ,Nucleic Acids, Nucleotides, and Nucleosides::Antisense Elements (Genetics)::RNA, Antisense::MicroRNAs [CHEMICALS AND DRUGS] ,Neoplasms::Neoplasms by Site::Breast Neoplasms [DISEASES] ,Mama - Càncer - Tractament ,Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores] ,terapéutica::tratamiento combinado::tratamiento neoadyuvante [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS] ,nucleótidos y nucleósidos de ácidos nucleicos::elementos antisentido (genética)::ARN antiparalelo::microARN [COMPUESTOS QUÍMICOS Y DROGAS] ,Other subheadings::Other subheadings::/drug therapy [Other subheadings] - Abstract
Cáncer de mama HER2 positivo; MicroARN circulante; Tratamiento neoadyuvante Càncer de mama HER2-positiu; MicroARN circulant; Tractament neoadjuvant HER2-positive breast cancer; Circulating microRNA; Neoadjuvant treatment Background: The absence of breast cancer cells in surgical specimens, i.e., pathological complete response (pCR), is widely recognized as a favorable prognostic factor after neoadjuvant therapy. In contrast, the presence of disease at surgery characterizes a prognostically heterogeneous group of patients. Here, we challenged circulating microRNAs (miRNAs) at the end of neoadjuvant therapy as potential prognostic biomarkers in the NeoALTTO study. Methods: Patients treated within the trastuzumab arm (i.e., pre-operative weekly trastuzumab for 6 weeks followed by the addition of weekly paclitaxel for 12 weeks; post-operative FEC for 3 cycles followed by trastuzumab up to complete 1 year of treatment) were randomized into a training (n= 54) and testing (n= 72) set. RT-PCR-based high-throughput miRNA profile was performed on plasma samples collected at the end of neoadjuvant treatment of both sets. After normalization, circulating miRNAs associated with event free survival (EFS) were identified by univariate and multivariate Cox regression model. Results: Starting from 23 circulating miRNAs associated with EFS in the training set, we generated a 3-circulating miRNA prognostic signature consisting of miR-185-5p, miR-146a-5p, miR-22-3p, which was confirmed in the testing set. The 3-circulating miRNA signature showed a C-statistic of 0.62 (95% confidence interval [95%CI] 0.53-0.71) in the entire study cohort. By resorting to a multivariate Cox regression model we found a statistical significant interaction between the expression values of miR-194-5p and pCR status (p.interaction =0.005) with an estimate Hazard Ratio (HR) of 1.83 (95%CI 1.14- 2.95) in patients with pCR, and 0.87 (95%CI 0.69-1.10) in those without pCR. Notably, the model including this interaction along with the abovementioned 3-circulating miRNA signature provided the highest discriminatory capability with a C-statistic of 0.67 (95%CI 0.58-0.76). Conclusions: Circulating miRNAs are informative to identify patients with different prognosis among those with heterogeneous response after trastuzumab-based neoadjuvant treatment, and may be an exploitable tool to select candidates for salvage adjuvant therapy. The NeoALTTO study was sponsored by GlaxoSmithKline; Lapatinib is an asset of Novartis AG as of March 2, 2015. This sub-study was supported by the Italian Ministry of Health to SC. No grant number is applicable, funds were obtained through a law that allows tax-payers to allocate the 5 × 1000 share of their payments to research.
- Published
- 2023
19. The Phylogeny of Psychrotrophic Bacteria Isolated from Refrigerated Raw Cow Milk Collected in an Arid Area of Algeria
- Author
-
K. Bouchair, L. Vannini, A. Boubendir, A. Bounamous, S. El Abed, Bouchair K., Boubendir A., El Abed S., Vannini L., and Bounamous A.
- Subjects
Veterinary medicine ,biology ,Cold storage ,Chryseobacterium ,refrigerated milk ,phylogeny ,biology.organism_classification ,medicine.disease_cause ,16S ribosomal RNA ,psychrotrophic bacteria ,General Biochemistry, Genetics and Molecular Biology ,arid area ,Psychrotrophic bacteria ,Enterococcus ,Aeromonas ,Algeria ,Lactobacillus ,medicine ,Stenotrophomonas ,Enterococcus faecali ,General Agricultural and Biological Sciences ,General Environmental Science - Abstract
–: The present study investigated the phylogeny based on 16S rRNA gene sequences of psychrotrophic bacteria isolated from refrigerated raw cow milk collected in an arid area of Algeria. During cold storage of milk at 4°C, 29 bacterial morpho-physiotypes were selected among 177 isolates and were identified by partial 16S rRNA gene sequencing. The results of the phylogenetic analysis showed five clusters regrouping six genera namely Stenotrophomonas, Acinetobacter, Chryseobacterium, Lactobacillus, Aeromonas and Enterococcus. Enterococcus constituted the largest cluster composed of 9 taxa with E. faecalis being the predominant species and it was the most subclustered group. The comparative genomic analysis based on 16S rRNA gene sequence of E. faecalis isolates, with related strains from different geographies and climates was performed. The observations of the genetic variation showed that seven E. faecalis strains (MH569850, MH569851, MH569854, MH569856, MH569857, MH569859 and MH569860) registered similarities of sequences less than 97%, which lead to the hypothesis that the isolates could represent a novel species of the genus Enterococcus. The minor richness of the milk microbiota analyzed in this arid region may account for the intervention of environmental factors influencing the selection and the evolution of the microflora.
- Published
- 2021
20. The effect of Dunaliella salina extracts on the adhesion of Pseudomonas aeruginosa to 3D printed polyethylene terephthalate and polylactic acid.
- Author
-
Bechar A, Er-Rahmani S, Hassi M, Sadiki M, El Abed S, Ouaddi O, Tizar F, Alouani M, and Ibnsouda Koraichi S
- Subjects
- Surface Properties, Chlorophyceae drug effects, Biofouling prevention & control, Plant Extracts pharmacology, Plant Extracts chemistry, Polyesters chemistry, Polyethylene Terephthalates chemistry, Bacterial Adhesion drug effects, Pseudomonas aeruginosa drug effects, Pseudomonas aeruginosa physiology, Printing, Three-Dimensional, Hydrophobic and Hydrophilic Interactions
- Abstract
Polyethylene terephthalate (PET) and polylactic acid (PLA) are among the polymers used in the food industry. In this study, crude extracts of Dunaliella salina were used to treat the surface of 3D printed materials studied, aiming to provide them with an anti-adhesive property against Pseudomonas aeruginosa . The hydrophobicity of treated and untreated surfaces was characterized using the contact angle method. Furthermore, the adhesive behavior of P. aeruginosa toward the substrata surfaces was also studied theoretically and experimentally. The results showed that the untreated PLA was hydrophobic, while the untreated PET was hydrophilic. It was also found that the treated materials became hydrophilic and electron-donating. The total energy of adhesion revealed that P. aeruginosa adhesion was theoretically favorable on untreated materials, while it was unfavorable on treated ones. Moreover, the experimental data proved that the adhesion to untreated substrata was obtained, while there was complete inhibition of adhesion to treated surfaces.
- Published
- 2024
- Full Text
- View/download PDF
21. Tumor Intrinsic Subtypes and Gene Expression Signatures in Early-Stage ERBB2/HER2-Positive Breast Cancer: A Pooled Analysis of CALGB 40601, NeoALTTO, and NSABP B-41 Trials.
- Author
-
Fernandez-Martinez A, Rediti M, Tang G, Pascual T, Hoadley KA, Venet D, Rashid NU, Spears PA, Islam MN, El-Abed S, Bliss J, Lambertini M, Di Cosimo S, Huobe J, Goerlitz D, Hu R, Lucas PC, Swain SM, Sotiriou C, Perou CM, and Carey LA
- Subjects
- Adult, Aged, Female, Humans, Middle Aged, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biomarkers, Tumor genetics, Gene Expression Profiling, Lapatinib administration & dosage, Lapatinib therapeutic use, Neoadjuvant Therapy, Neoplasm Staging, Retrospective Studies, Trastuzumab therapeutic use, Trastuzumab administration & dosage, Breast Neoplasms drug therapy, Breast Neoplasms genetics, Breast Neoplasms pathology, Receptor, ErbB-2 genetics, Transcriptome
- Abstract
Importance: Biologic features may affect pathologic complete response (pCR) and event-free survival (EFS) after neoadjuvant chemotherapy plus ERBB2/HER2 blockade in ERBB2/HER2-positive early breast cancer (EBC)., Objective: To define the quantitative association between pCR and EFS by intrinsic subtype and by other gene expression signatures in a pooled analysis of 3 phase 3 trials: CALGB 40601, NeoALTTO, and NSABP B-41., Design, Setting, and Participants: In this retrospective pooled analysis, 1289 patients with EBC received chemotherapy plus either trastuzumab, lapatinib, or the combination, with a combined median follow-up of 5.5 years. Gene expression profiling by RNA sequencing was obtained from 758 samples, and intrinsic subtypes and 618 gene expression signatures were calculated. Data analyses were performed from June 1, 2020, to January 1, 2023., Main Outcomes and Measures: The association of clinical variables and gene expression biomarkers with pCR and EFS were studied by logistic regression and Cox analyses., Results: In the pooled analysis, of 758 women, median age was 49 years, 12% were Asian, 6% Black, and 75% were White. Overall, pCR results were associated with EFS in the ERBB2-enriched (hazard ratio [HR], 0.45; 95% CI, 0.29-0.70; P < .001) and basal-like (HR, 0.19; 95% CI, 0.04-0.86; P = .03) subtypes but not in luminal A or B tumors. Dual trastuzumab plus lapatinib blockade over trastuzumab alone had a trend toward EFS benefit in the intention-to-treat population; however, in the ERBB2-enriched subtype there was a significant and independent EFS benefit of trastuzumab plus lapatinib vs trastuzumab alone (HR, 0.47; 95% CI, 0.27-0.83; P = .009). Overall, 275 of 618 gene expression signatures (44.5%) were significantly associated with pCR and 9 of 618 (1.5%) with EFS. The ERBB2/HER2 amplicon and multiple immune signatures were significantly associated with pCR. Luminal-related signatures were associated with lower pCR rates but better EFS, especially among patients with residual disease and independent of hormone receptor status. There was significant adjusted HR for pCR ranging from 0.45 to 0.81 (higher pCR) and 1.21-1.94 (lower pCR rate); significant adjusted HR for EFS ranged from 0.71 to 0.94., Conclusions and Relevance: In patients with ERBB2/HER2-positive EBC, the association between pCR and EFS differed by tumor intrinsic subtype, and the benefit of dual ERBB2/HER2 blockade was limited to ERBB2-enriched tumors. Immune-activated signatures were concordantly associated with higher pCR rates and better EFS, whereas luminal signatures were associated with lower pCR rates.
- Published
- 2024
- Full Text
- View/download PDF
22. The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study.
- Author
-
Martins-Branco D, Kassapian M, Debien V, Caparica R, Eiger D, Dafni U, Andriakopoulou C, El-Abed S, Ellard SL, Izquierdo M, Vicente M, Chumsri S, Piccart-Gebhart M, Moreno-Aspitia A, Knop AS, Lombard J, and de Azambuja E
- Subjects
- Humans, Female, Middle Aged, Trastuzumab adverse effects, Receptor, ErbB-2 metabolism, Erythropoiesis, Treatment Outcome, Disease-Free Survival, Chemotherapy, Adjuvant adverse effects, Antineoplastic Combined Chemotherapy Protocols adverse effects, Breast Neoplasms pathology
- Abstract
Purpose: To assess whether erythropoiesis-stimulating agents (ESA) administration impacts the outcomes of patients with HER2-positive early breast cancer (EBC)., Methods: ALTTO (NCT00490139) patients were categorized by ESA use during adjuvant anti-HER2 treatment. Disease-free-survival (DFS), overall survival (OS), and time-to-distant recurrence (TTDR) were analyzed by ESA administration, with subgroup analyses according to prognostic factors. Log-rank tests and Cox modeling were performed. Adverse events (AEs) of ESA-interest were compared., Results: Among 8381 patients recruited in ALTTO, 123 (1.5%) received ESA concomitantly with study treatment. The median age of patients receiving ESA was 54 years, 39.0% premenopausal, most had tumor size > 2 cm (56.9%), node-positive (58.5%), and positive estrogen receptor expression (61.8%). Median follow-up was shorter in the ESA group [6.1 years (IQR 5.3-7.0) vs. 6.9 years (6.0-7.1); p < 0.001]. There was no DFS difference by ESA administration (log-rank p = 0.70), with 3- and 7-year DFS of 89.2% (95% CI 81.8-93.8%) and 81.6% (71.4-88.5%) in ESA group vs. 88.3% (87.6-89.0%) and 80.0% (79.1-80.9%) in No-ESA group. In subgroup analyses, the interaction of ESA administration with menopausal status was statistically significant (unadjusted p = 0.024; stratified p = 0.033), favoring premenopausal women receiving ESA. We observed no significant association of ESA administration with OS (log-rank p = 0.57; 7-year OS in ESA 88.6% vs. 90.0% in non-ESA) or TTDR. ESA-interest AEs were experienced by eight (6.5%) patients receiving ESA and 417 (5.1%) in the No-ESA group (p = 0.41)., Conclusion: ESA administration to patients receiving adjuvant anti-HER2 treatment for HER2-positive EBC was safe and not associated with a negative impact on survival outcomes., (© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
23. Immunological and clinicopathological features predict HER2-positive breast cancer prognosis in the neoadjuvant NeoALTTO and CALGB 40601 randomized trials.
- Author
-
Rediti M, Fernandez-Martinez A, Venet D, Rothé F, Hoadley KA, Parker JS, Singh B, Campbell JD, Ballman KV, Hillman DW, Winer EP, El-Abed S, Piccart M, Di Cosimo S, Symmans WF, Krop IE, Salgado R, Loi S, Pusztai L, Perou CM, Carey LA, and Sotiriou C
- Subjects
- Female, Humans, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Hormones, Neoadjuvant Therapy, Randomized Controlled Trials as Topic, Receptor, ErbB-2 genetics, Receptor, ErbB-2 therapeutic use, Trastuzumab therapeutic use, Treatment Outcome, Tumor Microenvironment, Breast Neoplasms drug therapy, Breast Neoplasms genetics
- Abstract
The identification of prognostic markers in patients receiving neoadjuvant therapy is crucial for treatment optimization in HER2-positive breast cancer, with the immune microenvironment being a key factor. Here, we investigate the complexity of B and T cell receptor (BCR and TCR) repertoires in the context of two phase III trials, NeoALTTO and CALGB 40601, evaluating neoadjuvant paclitaxel with trastuzumab and/or lapatinib in women with HER2-positive breast cancer. BCR features, particularly the number of reads and clones, evenness and Gini index, are heterogeneous according to hormone receptor status and PAM50 subtypes. Moreover, BCR measures describing clonal expansion, namely evenness and Gini index, are independent prognostic factors. We present a model developed in NeoALTTO and validated in CALGB 40601 that can predict event-free survival (EFS) by integrating hormone receptor and clinical nodal status, breast pathological complete response (pCR), stromal tumor-infiltrating lymphocyte levels (%) and BCR repertoire evenness. A prognostic score derived from the model and including those variables, HER2-EveNT, allows the identification of patients with 5-year EFS > 90%, and, in those not achieving pCR, of a subgroup of immune-enriched tumors with an excellent outcome despite residual disease., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
24. Glucose control during Ramadan in a pediatric cohort with type 1 diabetes on MiniMed standard and advanced hybrid closed‑loop systems: A pilot study.
- Author
-
Wannes S, Gamal GM, Fredj MB, Al Qusayer D, El Abed S, Sedky Y, and Khalil M
- Abstract
Background: Hybrid closed-loop (HCL) systems have revolutionized the treatment of diabetes, enabling doctors to cope with challenging conditions that were previously almost impossible to manage or were very risky and difficult., Aims: To assess the efficacy and safety of a hybrid closed-loop (HCL) system during Ramadan fasting in a pediatric cohort with type 1 diabetes (T1D)., Research Design and Methods: Glucose control outcomes in older children and adolescents aged 8-16 years with automated insulin delivery for T1D were analyzed during Ramadan and 1 month before Ramadan. Participants on MiniMed standard HCL (670G) or advanced HCL (780G) systems of Medtronic were categorized as fasting or nonfasting., Results: The average age of the 19 participants (8 and 11 were on standard and advanced HCL systems, respectively) was 11.35 ± 2 years. Eleven patients fasted during Ramadan. Pump setup and sensor statistics were the same during Ramadan and the month before; no significant difference was found between the two groups in terms of insulin and glucose control metrics, with practically the same coefficient of variation, time in range (TIR) and time spent in hypoglycemia, maintained within the international recommended targets. Total daily doses were paradoxically higher in patients who fasted during Ramadan (p = 0.01), without repercussions on glucose control metrics., Conclusions: Standard and advanced HCL use during Ramadan were safe and were associated with a maintained optimum TIR (>70 %) and no significant hypoglycemia in adolescents and older children with T1D., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
25. The theoretical adhesion of Staphylococcus aureus and Pseudomonas aeruginosa as nosocomial pathogens on 3D printing filament materials.
- Author
-
Raouan SE, Zouine N, Harchli EE, El Abed S, Sadiki M, Ghachtouli NE, Lachkar M, and Ibnsouda SK
- Subjects
- Humans, Bacterial Adhesion, Pseudomonas aeruginosa, Staphylococcus aureus, Butadienes pharmacology, Polyethylene Terephthalates chemistry, Biofilms, Styrenes, Cross Infection, Acrylonitrile, Staphylococcal Infections
- Abstract
Microbial infections and nosocomial diseases associated with biomaterial have become a major problem of public health and largely lead to revision surgery, which is painful and quite expensive for patients. These infections are caused by formation of biofilm, which present a difficulty of treatment with conventional antibiotics. The aim of our study is to investigate the theoretical adhesion of Staphylococcus aureus and Pseudomonas aeruginosa on four 3-dimensional printing filament materials used in the manufacture of medical equipment. Thus, the physicochemical properties of these microorganisms and all filament materials were determined using the contact angle measurements. Our results indicated that bacterial surfaces were hydrophilic, strongly electron donating and weakly electron accepting. In contrast, nylon, acrylonitrile butadiene-styrene, polyethylene terephthalate, and polylactic acid surfaces were hydrophobic and more electron-donor than electron-acceptor. In addition, according to the values of total free interaction energy ΔG
Total , Staphylococcus aureus was found unable to adhere to the filament materials except polyethylene terephthalate surface. However, Pseudomonas aeruginosa showed adhesion capacity only for acrylonitrile butadiene-styrene and polyethylene terephthalate surfaces. These findings imply that the usage of these 3D printed materials in the medical area necessitates more research into enhancing their resistance to bacterial adherence., (© 2023. Institute of Microbiology, Academy of Sciences of the Czech Republic, v.v.i.)- Published
- 2023
- Full Text
- View/download PDF
26. Insulin pump therapy and glucose control during Ramadan fasting in an adolescent with type 1 diabetes: from an open-loop sensor-augmented pump therapy with predictive low-glucose management to an advanced hybrid closed-loop system.
- Author
-
Wannes S, Al Qusayer D, El Abed S, and Ben Fredj M
- Subjects
- Humans, Adolescent, Blood Glucose, Hypoglycemic Agents therapeutic use, Fasting, Insulin Infusion Systems, Insulin, Blood Glucose Self-Monitoring, Cross-Over Studies, Diabetes Mellitus, Type 1 drug therapy, Insulins therapeutic use
- Published
- 2023
- Full Text
- View/download PDF
27. Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer.
- Author
-
Partridge AH, Niman SM, Ruggeri M, Peccatori FA, Azim HA Jr, Colleoni M, Saura C, Shimizu C, Sætersdal AB, Kroep JR, Mailliez A, Warner E, Borges VF, Amant F, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Walshe JM, Ruíz-Borrego M, Moore HCF, Saunders C, Bjelic-Radisic V, Susnjar S, Cardoso F, Smith KL, Ferreiro T, Ribi K, Ruddy K, Kammler R, El-Abed S, Viale G, Piccart M, Korde LA, Goldhirsch A, Gelber RD, and Pagani O
- Subjects
- Adult, Female, Humans, Pregnancy, Antineoplastic Combined Chemotherapy Protocols, Chemotherapy, Adjuvant, Combined Modality Therapy, Disease-Free Survival, Neoplasm Recurrence, Local epidemiology, Neoplasm Recurrence, Local prevention & control, Neoplasm Recurrence, Local drug therapy, Prospective Studies, Withholding Treatment, Breast Neoplasms drug therapy
- Abstract
Background: Prospective data on the risk of recurrence among women with hormone receptor-positive early breast cancer who temporarily discontinue endocrine therapy to attempt pregnancy are lacking., Methods: We conducted a single-group trial in which we evaluated the temporary interruption of adjuvant endocrine therapy to attempt pregnancy in young women with previous breast cancer. Eligible women were 42 years of age or younger; had had stage I, II, or III disease; had received adjuvant endocrine therapy for 18 to 30 months; and desired pregnancy. The primary end point was the number of breast cancer events (defined as local, regional, or distant recurrence of invasive breast cancer or new contralateral invasive breast cancer) during follow-up. The primary analysis was planned to be performed after 1600 patient-years of follow-up. The prespecified safety threshold was the occurrence of 46 breast cancer events during this period. Breast cancer outcomes in this treatment-interruption group were compared with those in an external control cohort consisting of women who would have met the entry criteria for the current trial., Results: Among 516 women, the median age was 37 years, the median time from breast cancer diagnosis to enrollment was 29 months, and 93.4% had stage I or II disease. Among 497 women who were followed for pregnancy status, 368 (74.0%) had at least one pregnancy and 317 (63.8%) had at least one live birth. In total, 365 babies were born. At 1638 patient-years of follow-up (median follow-up, 41 months), 44 patients had a breast cancer event, a result that did not exceed the safety threshold. The 3-year incidence of breast cancer events was 8.9% (95% confidence interval [CI], 6.3 to 11.6) in the treatment-interruption group and 9.2% (95% CI, 7.6 to 10.8) in the control cohort., Conclusions: Among select women with previous hormone receptor-positive early breast cancer, temporary interruption of endocrine therapy to attempt pregnancy did not confer a greater short-term risk of breast cancer events, including distant recurrence, than that in the external control cohort. Further follow-up is critical to inform longer-term safety. (Funded by ETOP IBCSG Partners Foundation and others; POSITIVE ClinicalTrials.gov number, NCT02308085.)., (Copyright © 2023 Massachusetts Medical Society.)
- Published
- 2023
- Full Text
- View/download PDF
28. Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer.
- Author
-
Nuciforo P, Townend J, Piccart MJ, Fielding S, Gkolfi P, El-Abed S, de Azambuja E, Werutsky G, Bliss J, Moebus V, Colleoni M, Aspitia AM, Gomez H, Gombos A, Coccia-Portugal MA, Tseng LM, Kunz G, Lerzo G, Sohn J, Semiglazov V, Saura C, Kroep J, Ferro A, Cameron D, Gelber R, Huober J, and Di Cosimo S
- Subjects
- Humans, Female, Lapatinib therapeutic use, Neoadjuvant Therapy, Receptor, ErbB-2, Trastuzumab adverse effects, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Treatment Outcome, Breast Neoplasms pathology
- Abstract
Background: Dual anti-HER2-targeted therapy in breast cancer (BC) significantly increased the rate of pathological complete response (pCR) compared to single blockade when added to chemotherapy. However, limited data exist on the long-term impact on survival of the additional increase in pCR., Methods: Neoadjuvant lapatinib and/or trastuzumab treatment optimisation (NCT00553358) is an international, randomised, open-label, phase III study investigating the addition of lapatinib to chemotherapy plus trastuzumab in HER2-positive early BC. Ten-year event-free survival (EFS), overall survival (OS) and safety were assessed on intention-to-treat population. The association between pCR and EFS or OS was investigated in landmark population., Results: A total of 455 patients were randomised to receive lapatinib (154), trastuzumab (149) or the combination (152). Ten-year EFS estimates were 63% (95% confidence interval [CI], 54%-71%) in the lapatinib group, 64% (95% CI, 55%-72%) in the trastuzumab group and 67% (95% CI, 58%-74%) in the combination group. Ten-year OS rates were 76% (95% CI, 67%-83%), 75% (95% CI, 66%-82%) and 80% (95% CI, 73%-86%) in the lapatinib, trastuzumab and combination groups, respectively. Women who achieved a pCR had improved EFS (hazard ratio 0.48, 95% CI, 0.31-0.73) and OS (hazard ratio 0.37, 95% CI, 0.20-0.63) compared with those who did not. The numerical difference in survival according to pCR status was greater in women treated with the combination and those with hormone-receptor-negative tumours. There were no new or long-term safety concerns., Conclusions: Patients with HER2-positive BC showed a durable survival benefit of neoadjuvant anti-HER2, irrespective of treatment arm. Patients who achieve pCR have significantly better outcomes than patients without pCR., (Copyright © 2022 Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
29. End-of-neoadjuvant treatment circulating microRNAs and HER2-positive breast cancer patient prognosis: An exploratory analysis from NeoALTTO.
- Author
-
Di Cosimo S, Ciniselli CM, Pizzamiglio S, Cappelletti V, Silvestri M, El-Abed S, Izquierdo M, Bajji M, Nuciforo P, Huober J, Cameron D, Chia S, Gomez HL, Iorio MV, Vingiani A, Pruneri G, and Verderio P
- Abstract
Background: The absence of breast cancer cells in surgical specimens, i.e. , pathological complete response (pCR), is widely recognized as a favorable prognostic factor after neoadjuvant therapy. In contrast, the presence of disease at surgery characterizes a prognostically heterogeneous group of patients. Here, we challenged circulating microRNAs (miRNAs) at the end of neoadjuvant therapy as potential prognostic biomarkers in the NeoALTTO study., Methods: Patients treated within the trastuzumab arm ( i.e. , pre-operative weekly trastuzumab for 6 weeks followed by the addition of weekly paclitaxel for 12 weeks; post-operative FEC for 3 cycles followed by trastuzumab up to complete 1 year of treatment) were randomized into a training ( n = 54) and testing ( n = 72) set. RT-PCR-based high-throughput miRNA profile was performed on plasma samples collected at the end of neoadjuvant treatment of both sets. After normalization, circulating miRNAs associated with event free survival (EFS) were identified by univariate and multivariate Cox regression model., Results: Starting from 23 circulating miRNAs associated with EFS in the training set, we generated a 3-circulating miRNA prognostic signature consisting of miR-185-5p, miR-146a-5p, miR-22-3p, which was confirmed in the testing set. The 3-circulating miRNA signature showed a C-statistic of 0.62 (95% confidence interval [95%CI] 0.53-0.71) in the entire study cohort. By resorting to a multivariate Cox regression model we found a statistical significant interaction between the expression values of miR-194-5p and pCR status (p.interaction =0.005) with an estimate Hazard Ratio (HR) of 1.83 (95%CI 1.14- 2.95) in patients with pCR, and 0.87 (95%CI 0.69-1.10) in those without pCR. Notably, the model including this interaction along with the abovementioned 3-circulating miRNA signature provided the highest discriminatory capability with a C-statistic of 0.67 (95%CI 0.58-0.76)., Conclusions: Circulating miRNAs are informative to identify patients with different prognosis among those with heterogeneous response after trastuzumab-based neoadjuvant treatment, and may be an exploitable tool to select candidates for salvage adjuvant therapy., Competing Interests: SDC received fees for medical education from Novartis, Pierre-Fabre, and IQVIA; and the research grant IG 20774 from Fondazione Associazione Italiana Ricerca contro il Cancro AIRC; and served as “ad hoc” medical advisor for Medica Scientia Innovation Research MEDSIR, Barcelona Spain. SE-A received grants from Novartis during the conduct of the ALTTO study, and grants from Roche/Genentech and Pfizer outside of the submitted work. MI is employed at Novartis Pharma. HG received honoraria as speaker from AstraZeneca, Roche, BMS, and Novartis. PN received grants from Novartis, Roche/Genentech, MSD Oncology, Bayer, and Targos outside the submitted work. MB’s institution received a research grant for the conduct of the NeoALTTO study. JH received advisory boards and honoraria from Roche and research grants from Novartis. DC received grant support, consulting fees, and fees for independent data monitoring committee work from Roche, grant support and consulting fees from Novartis, fees for independent data monitoring committee work from Synthon, and consulting fees from Daiichi Sankyo, Samsung BIOEPSIS, Puma Biotechnology, Seattle Genetics, and Zymeworks all support paid to his institution. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Di Cosimo, Ciniselli, Pizzamiglio, Cappelletti, Silvestri, El-Abed, Izquierdo, Bajji, Nuciforo, Huober, Cameron, Chia, Gomez, Iorio, Vingiani, Pruneri and Verderio.)
- Published
- 2023
- Full Text
- View/download PDF
30. The effect of essential oils mixture on chitosan-based film surface energy and antiadhesion activity against foodborne bacteria.
- Author
-
Mouhoub A, Er Raouan S, Guendouz A, El Alaoui-Talibi Z, Ibnsouda Koraichi S, El Abed S, Delattre C, and El Modafar C
- Subjects
- Food Microbiology, Bacteria, Anti-Bacterial Agents pharmacology, Escherichia coli, Microbial Sensitivity Tests, Oils, Volatile pharmacology, Chitosan pharmacology
- Abstract
In the food sector, the formation of biofilms as a result of microbial adherence on food-grade surfaces causes a major problem resulting in significant economic losses. Thereby, this work aimed to elaborate a biodegradable film using chitosan (CS-film) and reinforce its antiadhesion activity by incorporating pelargonium, clove, thyme, and cinnamon essential oils (EOs). Firstly, the antibacterial activity of these EOs alone and combined against four foodborne bacteria were analyzed by the microdilution method. Synergism was observed in the case of EOs combination. Secondly, the physicochemical characteristics and antiadhesion behavior of the CS-films were assessed by the contact angle method and ESEM, respectively. Results revealed that the EOs mixture treatment impacted considerably the physicochemical characteristics of the CS-film and reduced its qualitative and quantitative hydrophobicity. Moreover, the treated CS-film showed a strong antiadhesion behavior against Enterococcus hirae, Pseudomonas aeruginosa, Escherichia coli, and Staphylococcus aureus with percentages of non-covered surface equal to 97.65 ± 1.43%, 98.76 ± 0.32%, 99.68 ± 0.28%, and 95.63 ± 1.32% respectively. From all these results, the CS-film treated with the mixture of EOs presents a great potential for application as surface coating and food packaging preventing microbial adhesion and thus, avoiding food contamination and spoilage., (© 2023. The Author(s), under exclusive licence to Springer Nature B.V.)
- Published
- 2023
- Full Text
- View/download PDF
31. Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer.
- Author
-
Lambertini M, Ceppi M, Anderson RA, Cameron DA, Bruzzone M, Franzoi MA, Massarotti C, El-Abed S, Wang Y, Lecocq C, Nuciforo P, Rolyance R, Pusztai L, Sohn J, Latocca MM, Arecco L, Pistilli B, Ruddy KJ, Ballestrero A, Del Mastro L, Peccatori FA, Partridge AH, Saura C, Untch M, Piccart M, Di Cosimo S, de Azambuja E, and Demeestere I
- Subjects
- Humans, Female, Adult, Paclitaxel adverse effects, Lapatinib therapeutic use, Biomarkers, Breast Neoplasms drug therapy, Breast Neoplasms surgery, Ovarian Reserve
- Abstract
Background: The potential gonadotoxicity of anti-HER2 agents remains largely unknown, and limited, conflicting evidence exists for taxanes. Antimüllerian hormone (AMH) is an established biomarker of ovarian reserve that may aid in quantifying anticancer treatment-induced gonadotoxicity., Patients and Methods: The present biomarker analysis of the randomized phase III neoadjuvant NeoALTTO trial included premenopausal women aged ≤45 years at diagnosis of HER2-positive early breast cancer with available frozen serum samples at baseline (ie, before anticancer treatments), at week 2 (ie, the "biological window" of anti-HER2 therapy alone), and/or at the time of surgery (ie, after completing paclitaxel + anti-HER2 therapy, before starting adjuvant chemotherapy)., Results: The present analysis included 130 patients with a median age of 38 years (interquartile ratio [IQR], age 33-42 years). AMH values at the 3 time points differed significantly (P<.001). At baseline, median AMH levels were 1.29 ng/mL (IQR, 0.56-2.62 ng/mL). At week 2, a small but significant reduction in AMH levels was observed (median, 1.10 ng/mL; IQR, 0.45-2.09 ng/mL; P<.001). At surgery, a larger significant decline in AMH levels was observed (median, 0.01 ng/mL; IQR, 0.01-0.03 ng/mL; P<.001). Although the type of anti-HER2 treatment (trastuzumab and/or lapatinib) did not seem to impact the results, age and pretreatment ovarian reserve had a major influence on treatment-induced gonadotoxicity risk., Conclusions: This NeoALTTO biomarker analysis showed that anti-HER2 therapies alone had limited gonadotoxicity but that the addition of weekly paclitaxel resulted in marked AMH decline with possible negative implications for subsequent ovarian function and fertility.
- Published
- 2023
- Full Text
- View/download PDF
32. Predictive Role of CD36 Expression in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Trastuzumab.
- Author
-
Ligorio F, Di Cosimo S, Verderio P, Ciniselli CM, Pizzamiglio S, Castagnoli L, Dugo M, Galbardi B, Salgado R, Loi S, Michiels S, Triulzi T, Tagliabue E, El-Abed S, Izquierdo M, de Azambuja E, Nuciforo P, Huober J, Moscetti L, Janni W, Coccia-Portugal MA, Corsetto PA, Belfiore A, Lorenzini D, Daidone MG, Vingiani A, Gianni L, Pupa SM, Bianchini G, Pruneri G, and Vernieri C
- Subjects
- Humans, Female, Trastuzumab, Receptor, ErbB-2 metabolism, Chemotherapy, Adjuvant, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Lapatinib, Treatment Outcome, Neoadjuvant Therapy, Breast Neoplasms drug therapy, Breast Neoplasms genetics, Breast Neoplasms pathology
- Abstract
Background: Despite huge efforts to identify biomarkers associated with long-term clinical outcomes in patients with early-stage HER2-positive breast cancer (HER2+ BC) treated with (neo)adjuvant anti-HER2 therapy, no reliable predictors have been identified so far. Fatty acid uptake, a process mediated by the transmembrane transporter CD36, has recently emerged as a potential determinant of resistance to anti-HER2 treatments in preclinical HER2+ BC models., Methods: Here, we investigated the association between baseline intratumor CD36 gene expression and event-free survival in 180 patients enrolled in the phase III trial Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimization (NeoALTTO), which randomly assigned stage II-III HER2+ BC patients to receive neoadjuvant lapatinib, trastuzumab, or lapatinib-trastuzumab in combination with chemotherapy. To this aim, we selected NeoALTTO trial patients for whom pretreatment whole transcriptomic data were available. The main study results were validated in an independent cohort of patients enrolled in the neoadjuvant phase II trial NeoSphere., Results: In 180 NeoALTTO patients, high intratumor CD36 expression was independently associated with worse event-free survival in patients treated with trastuzumab-based therapy (hazard ratio [HR] = 1.72, 95% confidence interval [CI] = 1.20 to 2.46), but not with lapatinib-based (HR = 1.02, 95% CI = 0.68 to 1.53) or trastuzumab-lapatinib-based (HR = 1.08, 95% CI = 0.60 to 1.94) therapy. Among 331 NeoSphere patients evaluated, high CD36 expression was independently associated with worse patient disease-free survival in both the whole study cohort (HR = 1.197, 95% CI = 1.002 to 1.428) and patients receiving trastuzumab-based neoadjuvant therapy (HR = 1.282, 95% CI = 1.049 to 1.568)., Conclusions: High CD36 expression predicts worse clinical outcomes in early-stage HER2+ BC treated with trastuzumab-based neoadjuvant therapy., (© The Author(s) 2022. Published by Oxford University Press.)
- Published
- 2022
- Full Text
- View/download PDF
33. PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer.
- Author
-
Agostinetto E, Ameye L, Martel S, Aftimos P, Pondé N, Maurer C, El-Abed S, Wang Y, Vicente M, Chumsri S, Bliss J, Kroep J, Colleoni M, Petrelli F, Del Mastro L, Moreno-Aspitia A, Piccart M, Paesmans M, de Azambuja E, and Lambertini M
- Abstract
The prognostic performance of PREDICT in patients with HER2-positive early breast cancer (EBC) treated in the modern era with effective chemotherapy and anti-HER2 targeted therapies is unclear. Therefore, we investigated its prognostic performance using data extracted from ALTTO, a phase III trial evaluating adjuvant lapatinib ± trastuzumab vs. trastuzumab alone in patients with HER2-positive EBC. Our analysis included 2794 patients. After a median follow-up of 6.0 years (IQR, 5.8-6.7), 182 deaths were observed. Overall, PREDICT underestimated 5-year OS by 6.7% (95% CI, 5.8-7.6): observed 5-year OS was 94.7% vs. predicted 88.0%. The underestimation was consistent across all subgroups, including those according to the type of anti HER2-therapy. The highest absolute differences were observed for patients with hormone receptor negative-disease, nodal involvement, and large tumor size (13.0%, 15.8%, and 15.3%, respectively). AUC under the ROC curve was 73.7% (95% CI 69.7-77.8) in the overall population, ranging between 61.7% and 77.7% across the analyzed subgroups. In conclusion, our analysis showed that PREDICT highly underestimated OS in HER2-positive EBC. Hence, it should be used with caution to give prognostic estimation to HER2-positive EBC patients treated in the modern era with effective chemotherapy and anti-HER2 targeted therapies., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
34. Cancer cells resist antibody-mediated destruction by neutrophils through activation of the exocyst complex.
- Author
-
van Rees DJ, Bouti P, Klein B, Verkuijlen PJH, van Houdt M, Schornagel K, Tool ATJ, Venet D, Sotiriou C, El-Abed S, Izquierdo M, Guillaume S, Saura C, Di Cosimo S, Huober J, Roylance R, Kim SB, Kuijpers TW, van Bruggen R, van den Berg TK, and Matlung HL
- Subjects
- Antibodies, Antibody-Dependent Cell Cytotoxicity, Female, Humans, RNA, Messenger, Trastuzumab pharmacology, Breast Neoplasms, Neutrophils
- Abstract
Background: Neutrophils kill antibody-opsonized tumor cells using trogocytosis, a unique mechanism of destruction of the target plasma. This previously unknown cytotoxic process of neutrophils is dependent on antibody opsonization, Fcγ receptors and CD11b/CD18 integrins. Here, we demonstrate that tumor cells can escape neutrophil-mediated cytotoxicity by calcium (Ca
2+ )-dependent and exocyst complex-dependent plasma membrane repair., Methods: We knocked down EXOC7 or EXOC4, two exocyst components, to evaluate their involvement in tumor cell membrane repair after neutrophil-induced trogocytosis. We used live cell microscopy and flow cytometry for visualization of the host and tumor cell interaction and tumor cell membrane repair. Last, we reported the mRNA levels of exocyst in breast cancer tumors in correlation to the response in trastuzumab-treated patients., Results: We found that tumor cells can evade neutrophil antibody-dependent cellular cytotoxicity (ADCC) by Ca2+ -dependent cell membrane repair, a process induced upon neutrophil trogocytosis. Absence of exocyst components EXOC7 or EXOC4 rendered tumor cells vulnerable to neutrophil-mediated ADCC (but not natural killer cell-mediated killing), while neutrophil trogocytosis remained unaltered. Finally, mRNA levels of exocyst components in trastuzumab-treated patients were inversely correlated to complete response to therapy., Conclusions: Our results support that neutrophil attack towards antibody-opsonized cancer cells by trogocytosis induces an active repair process by the exocyst complex in vitro. Our findings provide insight to the possible contribution of neutrophils in current antibody therapies and the tolerance mechanism of tumor cells and support further studies for potential use of the exocyst components as clinical biomarkers., Competing Interests: Competing interests: TKvdB is the inventor of patent EP2282772, owned by Stichting Sanquin Bloedvoorziening, entitled ‘Compositions and Methods to Enhance the Immune System’, which describes targeting CD47–SIRPα interactions during antibody therapy in cancer., (© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)- Published
- 2022
- Full Text
- View/download PDF
35. Microwave Imaging for Early Breast Cancer Detection: Current State, Challenges, and Future Directions.
- Author
-
AlSawaftah N, El-Abed S, Dhou S, and Zakaria A
- Abstract
Breast cancer is the most commonly diagnosed cancer type and is the leading cause of cancer-related death among females worldwide. Breast screening and early detection are currently the most successful approaches for the management and treatment of this disease. Several imaging modalities are currently utilized for detecting breast cancer, of which microwave imaging (MWI) is gaining quite a lot of attention as a promising diagnostic tool for early breast cancer detection. MWI is a noninvasive, relatively inexpensive, fast, convenient, and safe screening tool. The purpose of this paper is to provide an up-to-date survey of the principles, developments, and current research status of MWI for breast cancer detection. This paper is structured into two sections; the first is an overview of current MWI techniques used for detecting breast cancer, followed by an explanation of the working principle behind MWI and its various types, namely, microwave tomography and radar-based imaging. In the second section, a review of the initial experiments along with more recent studies on the use of MWI for breast cancer detection is presented. Furthermore, the paper summarizes the challenges facing MWI as a breast cancer detection tool and provides future research directions. On the whole, MWI has proven its potential as a screening tool for breast cancer detection, both as a standalone or complementary technique. However, there are a few challenges that need to be addressed to unlock the full potential of this imaging modality and translate it to clinical settings.
- Published
- 2022
- Full Text
- View/download PDF
36. The Effect of Oral Probiotics (Streptococcus Salivarius k12) on the Salivary Level of Secretory Immunoglobulin A, Salivation Rate, and Oral Biofilm: A Pilot Randomized Clinical Trial.
- Author
-
Babina K, Salikhova D, Polyakova M, Svitich O, Samoylikov R, Ahmad El-Abed S, Zaytsev A, and Novozhilova N
- Subjects
- Biofilms, Humans, Immunoglobulin A, Secretory, Pilot Projects, Saliva, Salivation, Probiotics, Streptococcus salivarius
- Abstract
We aimed to assess the effect of oral probiotics containing the Streptococcus salivarius K12 strain on the salivary level of secretory immunoglobulin A, salivation rate, and oral biofilm. Thirty-one consenting patients meeting the inclusion criteria were recruited in this double-blind, placebo-controlled, two-arm, parallel-group study and randomly divided into probiotic ( n = 15) and placebo ( n = 16) groups. Unstimulated salivation rate, concentration of salivary secretory immunoglobulin A, Turesky index, and Papillary-Marginal-Attached index were assessed after 4 weeks of intervention and 2 weeks of washout. Thirty patients completed the entire study protocol. We found no increase in salivary secretory immunoglobulin A levels and salivary flow rates in the probiotic group compared with placebo. Baseline and outcome salivary secretory immunoglobulin A concentrations (mg/L) were 226 ± 130 and 200 ± 113 for the probiotic group and 205 ± 92 and 191 ± 97 for the placebo group, respectively. A significant decrease in plaque accumulation was observed in the probiotic group at 4 and 6 weeks. Within the limitations of the present study, it may be concluded that probiotic intake ( Streptococcus salivarius K12) does not affect salivation rates and secretory immunoglobulin A salivary levels but exhibits a positive effect on plaque accumulation. Trial registration NCT05039320. Funding: none.
- Published
- 2022
- Full Text
- View/download PDF
37. Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03).
- Author
-
Mayer EL, Fesl C, Hlauschek D, Garcia-Estevez L, Burstein HJ, Zdenkowski N, Wette V, Miller KD, Balic M, Mayer IA, Cameron D, Winer EP, Ponce Lorenzo JJ, Lake D, Pristauz-Telsnigg G, Haddad TC, Shepherd L, Iwata H, Goetz M, Cardoso F, Traina TA, Sabanathan D, Breitenstein U, Ackerl K, Metzger Filho O, Zehetner K, Solomon K, El-Abed S, Theall KP, Lu DR, Dueck A, Gnant M, and DeMichele A
- Subjects
- Antineoplastic Agents, Hormonal adverse effects, Antineoplastic Combined Chemotherapy Protocols adverse effects, Breast Neoplasms enzymology, Breast Neoplasms pathology, Chemotherapy, Adjuvant, Disease-Free Survival, Female, Humans, Neoplasm Staging, Piperazines adverse effects, Protein Kinase Inhibitors adverse effects, Pyridines adverse effects, Risk Factors, Time Factors, Antineoplastic Agents, Hormonal therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Breast Neoplasms drug therapy, Piperazines therapeutic use, Protein Kinase Inhibitors therapeutic use, Pyridines therapeutic use, Receptor, ErbB-2 analysis, Receptors, Estrogen analysis, Receptors, Progesterone analysis
- Abstract
Purpose: The PALLAS study investigated whether the addition of palbociclib, an oral CDK4/6 inhibitor, to adjuvant endocrine therapy (ET) improves invasive disease-free survival (iDFS) in early hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. In this analysis, we evaluated palbociclib exposure and discontinuation in PALLAS., Methods: Patients with stage II-III HR+, HER2- disease were randomly assigned to 2 years of palbociclib with adjuvant ET versus ET alone. The primary objective was to compare iDFS between arms. Continuous monitoring of toxicity, dose modifications, and early discontinuation was performed. Association of baseline covariates with time to palbociclib reduction and discontinuation was analyzed with multivariable competing risk models. Landmark and inverse probability weighted per-protocol analyses were performed to assess the impact of drug persistence and exposure on iDFS., Results: Of the 5,743 patient analysis population (2,840 initiating palbociclib), 1,199 (42.2%) stopped palbociclib before 2 years, the majority (772, 27.2%) for adverse effects, most commonly neutropenia and fatigue. Discontinuation of ET did not differ between arms. Discontinuations for non-protocol-defined reasons were greater in the first 3 months of palbociclib, and in the first calendar year of accrual, and declined over time. No significant relationship was seen between longer palbociclib duration or ≥ 70% exposure intensity and improved iDFS. In the weighted per-protocol analysis, no improvement in iDFS was observed in patients receiving palbociclib versus not (hazard ratio 0.89; 95% CI, 0.72 to 1.11)., Conclusion: Despite observed rates of discontinuation in PALLAS, analyses suggest that the lack of significant iDFS difference between arms was not directly related to inadequate palbociclib exposure. However, the discontinuation rate illustrates the challenge of introducing novel adjuvant treatments, and the need for interventions to improve persistence with oral cancer therapies., Competing Interests: Erica L. MayerConsulting or Advisory Role: Lilly, Novartis, AstraZeneca, Gilead SciencesResearch Funding: Pfizer (Inst) Christian FeslResearch Funding: Pfizer (Inst) Dominik HlauschekResearch Funding: Pfizer (Inst) Laura Garcia-EstevezConsulting or Advisory Role: Daiichi Sankyo/Astra Zeneca, Palex, Seattle GeneticsResearch Funding: Roche/Genentech (Inst) Nicholas ZdenkowskiHonoraria: Roche, Pfizer, EisaiConsulting or Advisory Role: Lilly, AstraZeneca, EisaiResearch Funding: Roche (Inst), Pfizer (Inst)Travel, Accommodations, Expenses: Roche, Amgen, Novartis Kathy D. MillerThis author is the Senior Deputy Editor of Journal of Clinical Oncology. Journal policy recused the author from having any role in the peer review of this manuscript.Consulting or Advisory Role: Merck, Genentech/Roche, Athenex, AstraZeneca, Bristol Myers Squibb/CelgeneResearch Funding: Taiho Pharmaceutical (Inst), Novartis (Inst), Seattle Genetics (Inst), Pfizer (Inst), Astex Pharmaceuticals (Inst), British Biotech (Inst), CytomX Therapeutics (Inst), Alphamab (Inst) Marija BalicConsulting or Advisory Role: Amgen, AstraZeneca, Daiichi Sankyo/Astra Zeneca, Lilly, MSD, Novartis, Pierre Fabre, Pfizer, Roche, SamsungSpeakers' Bureau: Amgen, AstraZeneca, Daiichi Sankyo/Astra Zeneca, Lilly, Novartis, Pierre Fabre, Pfizer, Roche, Seattle GeneticsResearch Funding: Lilly (Inst), Novartis (Inst), Pfizer (Inst)Travel, Accommodations, Expenses: MSD Ingrid A. MayerConsulting or Advisory Role: Novartis, AstraZeneca, Lilly, Genentech, GlaxoSmithKline, Immunomedics, Macrogenics, Pfizer, AbbVie, Seattle Genetics, Puma Biotechnology, Cyclacel, Blueprint Medicines, SanofiResearch Funding: Novartis (Inst), Pfizer (Inst), Genentech (Inst) David CameronConsulting or Advisory Role: Lilly (Inst), Novartis (Inst), Novartis (Inst), Research Triangle Institute RTI Health Solutions (Inst), Daiichi Sankyo (Inst), Prima BioMed (Inst), Merck Sharp & Dohme (Inst), Zymeworks (Inst), Eisai (Inst), Puma Biotechnology (Inst), Pfizer (Inst), Oncolytics (Inst), Roche (Inst), Roche (Inst), Samsung Bioepis (Inst), Seattle Genetics (Inst), Synthon (Inst), Clarity Pharmaceuticals (Inst), Bexon/Zymeworks (Inst), Sanofi (Inst)Research Funding: Roche (Inst), Novartis (Inst), AstraZeneca (Inst) Eric P. WinerHonoraria: Genentech/Roche, Genomic HealthConsulting or Advisory Role: Leap Therapeutics, Seattle Genetics, Jounce Therapeutics, GlaxoSmithKline, Carrick Therapeutics, Lilly, G1 Therapeutics, Syros Pharmaceuticals, Genentech/Roche, Gilead Sciences, Zymeworks, AthenexResearch Funding: Genentech (Inst)Other Relationship: InfiniteMD José Juan Ponce LorenzoHonoraria: Seattle Genetics, Novartis, Pfizer, AstraZeneca/Daiichi Sankyo, Lilly, RocheConsulting or Advisory Role: Seattle Genetics, Novartis, AstraZeneca/Daiichi Sankyo, Roche Tufia C. HaddadResearch Funding: Takeda (Inst) Hiroji IwataHonoraria: Chugai Pharma, AstraZeneca, Eisai, Pfizer, Daiichi Sankyo, Lilly Japan, Kyowa Hakko Kirin, Taiho PharmaceuticalConsulting or Advisory Role: Chugai Pharma, Daiichi Sankyo, Pfizer, AstraZeneca, Lilly Japan, Kyowa Hakko Kirin, NovartisResearch Funding: MSD (Inst), AstraZeneca (Inst), Kyowa Hakko Kirin (Inst), Daiichi Sankyo (Inst), Chugai Pharma (Inst), Nihonkayaku (Inst), Lilly Japan (Inst), Novartis (Inst), Bayer (Inst), Pfizer (Inst), Boehringer Ingelheim (Inst), Sanofi (Inst) Matthew GoetzConsulting or Advisory Role: Lilly, bioTheranostics, Genomic Health, Novartis, Eisai, Sermonix Pharmaceuticals, Context Therapeutics, Pfizer, BiovicaResearch Funding: Lilly (Inst), Pfizer (Inst), Sermonix Pharmaceuticals (Inst)Patents, Royalties, Other Intellectual Property: Methods and Materials for Assessing Chemotherapy Responsiveness and Treating Cancer, Methods and Materials for Using Butyrylcholinesterases to Treat Cancer, Development of Human Tumor Xenografts from Women with Breast Cancer Treated with Neoadjuvant Chemotherapy (Inst)Travel, Accommodations, Expenses: Lilly Fatima CardosoConsulting or Advisory Role: Roche, Novartis, Pfizer, AstraZeneca, Teva, Astellas Pharma, Merus, Celgene, Eisai, Daiichi Sankyo, Genentech, Merck Sharp & Dohme, Sanofi, Pierre Fabre, Macrogenics, Amgen, GE Healthcare, GlaxoSmithKline, Mylan, Mundipharma, Seattle Genetics, Samsung Bioepis, Medscape, Prime OncologyTravel, Accommodations, Expenses: Pfizer, Roche, AstraZeneca Tiffany A. TrainaConsulting or Advisory Role: Genentech/Roche, Pfizer, AstraZeneca, Merck, Puma Biotechnology, Athenex, Daiichi Sankyo, Ionis Pharmaceuticals, Seattle Genetics, Eisai, Exact Sciences, Foundation Medicine, Ayala Pharmaceuticals, Gilead Sciences, Blueprint Medicines, Ellipses Pharma, Fuji Pharma, ITeos Therapeutics, AgendiaResearch Funding: Eisai (Inst), Pfizer (Inst), Novartis (Inst), Innocrin Pharma (Inst), AstraZeneca (Inst), Astellas Pharma (Inst), Immunomedics (Inst), Genentech/Roche (Inst), Daiichi Sankyo (Inst), Carrick Pharm (Inst), Ayala Pharmaceuticals (Inst) Urs BreitensteinConsulting or Advisory Role: AstraZeneca (Inst), Elie Lilly (Inst), Novartis (Inst), Pierre Fabre (Inst), Roche (Inst) Kerstin AckerlResearch Funding: Pfizer (Inst) Otto Metzger FilhoHonoraria: Grupo Oncoclinicas, RocheResearch Funding: Susan G. Komen for the Cure (Inst), Pfizer (Inst), Roche/Genentech (Inst), Eisai (Inst), Cascadian Therapeutics (Inst), AbbVie (Inst)Travel, Accommodations, Expenses: Grupo Oncoclinicas Karin ZehetnerResearch Funding: Pfizer (Inst) Kadine SolomonEmployment: Alliance Foundation TrialsStock and Other Ownership Interests: Pfizer, Merck, Moderna Therapeutics Sarra El-AbedEmployment: Astellas Pharma (I), argenx (I)Research Funding: Novartis (Inst), Roche/Genentech (Inst), Pfizer (Inst) Kathy Puyana TheallEmployment: Pfizer (I)Stock and Other Ownership Interests: Pfizer (I)Honoraria: PfizerTravel, Accommodations, Expenses: Pfizer Dongrui Ray LuEmployment: PfizerStock and Other Ownership Interests: Pfizer Amylou DueckPatents, Royalties, Other Intellectual Property: Royalties from licensing fees for a patient symptom questionnaire (MPN-SAF) Michael GnantEmployment: Sandoz (I)Honoraria: Amgen, Novartis, AstraZeneca, LillyConsulting or Advisory Role: Daiichi-Sankyo, Veracyte, Tolmar, LifeBrain, Lilly Angela DeMicheleResearch Funding: Pfizer (Inst), Genentech (Inst), Calithera Biosciences (Inst), Novartis (Inst)No other potential conflicts of interest were reported.
- Published
- 2022
- Full Text
- View/download PDF
38. What if the future of HER2-positive breast cancer patients was written in miRNAs? An exploratory analysis from NeoALTTO study.
- Author
-
Pizzamiglio S, Cosentino G, Ciniselli CM, De Cecco L, Cataldo A, Plantamura I, Triulzi T, El-Abed S, Wang Y, Bajji M, Nuciforo P, Huober J, Ellard SL, Rimm DL, Gombos A, Daidone MG, Verderio P, Tagliabue E, Di Cosimo S, and Iorio MV
- Subjects
- Breast Neoplasms pathology, Female, Humans, Middle Aged, Neoadjuvant Therapy, Prognosis, Proportional Hazards Models, Receptor, ErbB-2 antagonists & inhibitors, Trastuzumab administration & dosage, Trastuzumab adverse effects, Trastuzumab therapeutic use, Treatment Outcome, Tumor Burden, Biomarkers, Tumor, Breast Neoplasms drug therapy, Breast Neoplasms genetics, MicroRNAs genetics, Receptor, ErbB-2 genetics
- Abstract
Background: Neoadjuvant therapy with dual HER2 blockade improved pathological complete response (pCR) rate in HER2-positive breast cancer patients. Nevertheless, it would be desirable to identify patients exquisitely responsive to single agent trastuzumab to minimize or avoid overtreatment. Herein, we evaluated the predictive and prognostic value of basal primary tumor miRNA expression profile within the trastuzumab arm of NeoALTTO study (ClinicalTrials.gov Identifier: NCT00553358)., Methods: RNA samples from baseline biopsies were randomized into training (n = 45) and testing (n = 47) sets. After normalization, miRNAs associated with Event-free survival (EFS) and pCR were identified by univariate analysis. Multivariate models were implemented to generate specific signatures which were first confirmed, and then analyzed together with other clinical and pathological variables., Results: We identified a prognostic signature including hsa-miR-153-3p (HR 1.831, 95% CI: 1.34-2.50) and hsa-miR-219a-5p (HR 0.629, 95% CI: 0.50-0.78). For two additional miRNAs (miR-215-5p and miR-30c-2-3p), we found a statistically significant interaction term with pCR (p.interaction: 0.017 and 0.038, respectively). Besides, a two-miRNA signature was predictive of pCR (hsa-miR-31-3p, OR 0.70, 95% CI: 0.53-0.92, and hsa-miR-382-3p, OR: 1.39, 95% CI: 1.01-1.91). Notably, the performance of this predictive miRNA signature resembled that of the genomic classifiers PAM50 and TRAR, and did not improve when the extended models were fitted., Conclusion: Analyses of primary tumor tissue miRNAs hold the potential of a parsimonious tool to identify patients with differential clinical outcomes after trastuzumab based neoadjuvant therapy., (© 2021 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
39. Alpha-smooth Muscle Actin Expression in the Stroma Predicts Resistance to Trastuzumab in Patients with Early-stage HER2-positive Breast Cancer.
- Author
-
Vathiotis IA, Moutafi MK, Divakar P, Aung TN, Qing T, Fernandez A, Yaghoobi V, El-Abed S, Wang Y, Guillaume S, Nuciforo P, Huober J, Di Cosimo S, Kim SB, Harbeck N, Gomez H, Shafi S, Syrigos KN, Fountzilas G, Sotiriou C, Pusztai L, Warren S, and Rimm DL
- Subjects
- Actins, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Chemotherapy, Adjuvant, Disease-Free Survival, Female, Humans, Muscle, Smooth metabolism, Neoadjuvant Therapy, Receptor, ErbB-2 metabolism, Trastuzumab therapeutic use, Treatment Outcome, Breast Neoplasms drug therapy, Breast Neoplasms genetics, Breast Neoplasms metabolism
- Abstract
Purpose: The companion diagnostic test for trastuzumab has not changed much in the last 25 years. We used high-plex digital spatial profiling to identify biomarkers besides HER2 that can help predict response to trastuzumab in HER2-positive breast cancer., Experimental Design: Fifty-eight protein targets were measured in three different molecularly defined compartments by the NanoString GeoMx Digital Spatial Profiler (DSP) in a tissue microarray containing 151 patients with breast cancer that received adjuvant trastuzumab as part of the Hellenic Cooperative Oncology Group 10/05 clinical trial. Promising candidate biomarkers were orthogonally validated with quantitative immunofluorescence (QIF). RNA-sequencing data from the Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation Study (NeoALTTO) were accessed to provide independent cohort validation. Disease-free survival (DFS) was the main outcome assessed. Statistical analyses were performed using a two-sided test (α = 0.05) and multiple testing correction (Benjamini-Hochberg method, FDR < 0.1)., Results: By DSP, high expression of alpha-smooth muscle actin (α-SMA), both in the leukocyte and stromal compartments, was associated with shorter DFS in univariate analysis ( P = 0.002 and P = 0.023, respectively). High α-SMA expression in the stroma was validated by QIF after controlling for estrogen receptor and progesterone receptor status [HR, 3.12; 95% confidence interval (CI), 1.12-8.68; P = 0.029] showing recurrence on trastuzumab in the same cohort. In the NeoALTTO cohort, elevated levels of ACTA2 were predictive for shorter DFS in the multivariate analysis (HR, 3.21; 95% CI, 1.14-9.05; P = 0.027)., Conclusions: This work identifies α-SMA as a novel, easy-to-implement biomarker of resistance to trastuzumab that may be valuable in settings where trastuzumab is combined with other therapies., (©2021 American Association for Cancer Research.)
- Published
- 2021
- Full Text
- View/download PDF
40. Copy Number Aberration Analysis to Predict Response to Neoadjuvant Anti-HER2 Therapy: Results from the NeoALTTO Phase III Clinical Trial.
- Author
-
Venet D, Rediti M, Maetens M, Fumagalli D, Brown DN, Majjaj S, Salgado R, Pusztai L, Harbeck N, El-Abed S, Wang Y, Saura C, Gomez H, Semiglazov VF, de Azambuja E, Huober J, Nuciforo P, Di Cosimo S, Piccart M, Loi S, Rothé F, and Sotiriou C
- Subjects
- Antineoplastic Combined Chemotherapy Protocols therapeutic use, DNA Copy Number Variations, Female, Humans, Neoplasm Recurrence, Local, Receptor, ErbB-2 genetics, Receptor, ErbB-2 therapeutic use, Trastuzumab therapeutic use, Breast Neoplasms drug therapy, Breast Neoplasms genetics, Neoadjuvant Therapy
- Abstract
Purpose: The heterogeneity of response to anti-HER2 agents represents a major challenge in patients with HER2-positive breast cancer. To better understand the sensitivity and resistance to trastuzumab and lapatinib, we investigated the role of copy number aberrations (CNA) in predicting pathologic complete response (pCR) and survival outcomes in the NeoALTTO trial., Experimental Design: The neoadjuvant phase III NeoALTTO trial enrolled 455 patients with HER2-positive early-stage breast cancer. DNA samples from 269 patients were assessed for genome-wide copy number profiling. Recurrent CNAs were found with GISTIC2.0., Results: CNA estimates were obtained for 184 patients included in NeoALTTO. Among those, matched transcriptome and whole-exome data were available for 154 and 181 patients, respectively. A significant association between gene copy number and pCR was demonstrated for ERBB2 amplification. Nevertheless, ERBB2 amplification ceased to be predictive once ERBB2 expression level was considered. GISTIC2.0 analysis revealed 159 recurrent CNA regions. Lower copy number levels of the 6q23-24 locus predicted absence of pCR in the whole cohort and in the estrogen receptor-positive subgroup. 6q23-24 deletion was significantly more frequent in TP53 wild-type (WT) compared with TP53 -mutated, resulting in copy number levels significantly associated with lack of pCR only in the TP53 WT subgroup. Interestingly, a gene-ontology analysis highlighted several immune processes correlated to 6q23-24 copy number., Conclusions: Our analysis identified ERBB2 copy number as well as 6q23-24 CNAs as predictors of response to anti-HER2-based treatment. ERBB2 expression outperformed ERBB2 amplification. The complexity of the 6q23-24 region warrants further investigation., (©2021 American Association for Cancer Research.)
- Published
- 2021
- Full Text
- View/download PDF
41. Salvia officinalis extract mitigates the microbiologically influenced corrosion of 304L stainless steel by Pseudomonas aeruginosa biofilm.
- Author
-
Lekbach Y, Li Z, Xu D, El Abed S, Dong Y, Liu D, Gu T, Koraichi SI, Yang K, and Wang F
- Subjects
- Adsorption, Chromatography, High Pressure Liquid methods, Dielectric Spectroscopy, Mass Spectrometry methods, Microbial Sensitivity Tests, Seawater, Surface Properties, Anti-Bacterial Agents pharmacology, Biofilms drug effects, Corrosion, Plant Extracts pharmacology, Pseudomonas aeruginosa drug effects, Salvia officinalis chemistry, Stainless Steel chemistry
- Abstract
The mitigation of microbiologically influenced corrosion (MIC) of 304L stainless steel (SS) against Pseudomonas aeruginosa by a Salvia officinalis extract was investigated using electrochemical and surface analysis techniques. The extract was characterized by HPLC-Q-TOF-MS and its antibiofilm property was evaluated. The data revealed the presence of well-known antimicrobial and anticorrosion compounds in the extract. The S. officinalis extract was found effective in preventing biofilm formation and inhibiting mature biofilm. Electrochemical results indicated that P. aeruginosa accelerated the MIC of 304L SS, while the extract was found to prevent the MIC with an inhibition efficiency of 97.5 ± 1.5%. This was attributed to the formation of a protective film by the adsorption of some compounds from the extract on the 304L SS surface., (Copyright © 2019 Elsevier B.V. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
42. Nitinol as a suitable anode material for electricity generation in microbial fuel cells.
- Author
-
Taşkan E, Bulak S, Taşkan B, Şaşmaz M, El Abed S, and El Abed A
- Subjects
- Bacterial Adhesion, Biofilms, Denaturing Gradient Gel Electrophoresis methods, Dielectric Spectroscopy, Electric Conductivity, Microscopy, Electron, Scanning, Polymerase Chain Reaction methods, Proteobacteria classification, Proteobacteria physiology, Surface Properties, Alloys pharmacology, Bioelectric Energy Sources, Electrodes
- Abstract
Nitinols (Nickel-titanium alloys) have a good electrical conductivity and biocompatibility with human tissue and bacteria and, therefore, can be effectively used as an anode material in bioelectrochemical systems. This paper aimed to use nitinols (at different Ni/Ti ratios) as an anode material for microbial fuel cells (MFCs) in order to achieve higher power density. The maximum power densities of the MFCs using NiTi-1, NiTi-2, and NiTi-3 electrodes were 555 mW/m
2 , 811 mW/m2 , and 652 mW/m2 , respectively. More bacterial adhesion was observed on the NiTi-2 electrode. Electrochemical impedance spectroscopy (EIS) results showed low charge transfer resistance at MFCs fabricated with NiTi. The biofilm observations indicate that bacterial attachment is better with NiTi-2 as compared with that on NiTi-1 and NiTi-3. The resulting mesopore and macropore rich structure significantly promote microbial colonization, enabling formation of compact electroactive biofilms with additional benefit from the excellent biocompatibility and chemical stability of NiTi-2. Polymerase Chain Reaction-Denaturing Gradient Gel Electrophoresis (PCR-DGGE) results indicated that five groups of bacteria were the dominant phyla in the MFCs: environmental samples, b-proteobacteria, g-proteobacteria, d-proteobacteria, and CFB group bacteria. The high biocompatibility, electrical conductivity and stability of nitinols make them a more attractive anode material for MFCs., (Copyright © 2019 Elsevier B.V. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
43. Environmental Scanning Electron Microscopy characterization of the adhesion of conidia from Penicillium expansum to cedar wood substrata at different pH values.
- Author
-
El Abed S, Ibnsouda SK, Latrache H, Meftah H, Tahri NJ, and Hamadi F
- Subjects
- Cedrus chemistry, Hydrogen-Ion Concentration, Hydrophobic and Hydrophilic Interactions, Image Processing, Computer-Assisted, Microscopy, Electron, Scanning, Wood chemistry, Wood microbiology, Cedrus microbiology, Cell Adhesion, Penicillium physiology, Spores, Fungal physiology
- Abstract
Initial microbial adhesion to surfaces is a complicated process that is affected by a number of factors. An important property of a solution that may influence adhesion is pH. The surface properties of the cedar wood were characterized by the sessile drop technique. Moreover, the interfacial free energy of surface adhesion to the cedar wood was determined under pH values (2, 3, 5, 7, 9 and 11). The results showed that cedar wood examined at different pH levels could be considered hydrophobic ranged from Giwi = -13.1 mJ/m(2) to Giwi = -75 mJ/m(2). We noted that the electron-donor character of cedar wood was important at both basic and limit acidic conditions (pH 11 and pH 3) and it decreased at intermediate pH (pH 5). The cedar wood substratum presents a weak electron acceptor under various pH's. In addition, the adhesion of conidia from Penicilllium expansum to the cedar wood surfaces at different pH values (2, 3, 5, 7, 9 and 11) was investigated using Environmental Scanning Electron Microscopy and image analysis was assessed with the Mathlab(®) program. The data analysis showed that the conidia from P. expansum were strongly influenced by the pH. The maximum adhesion occurs in the pH 11 and pH 3 and decreased to 24% at pH 5.
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.